Introduction
Activation of receptor tyrosine kinases (RTK) is a key event in a number of developmental processes. The FLT3 RTK acts in concert with the related KIT receptor to ensure the proper development of hematopoietic and immune tissues. 1 This has been revealed by the analysis of KIT loss-of-function mutants and FLT3 gene knockout mice which demonstrate hematopoietic stem cell deficiencies in both mutants as well as more specific abnormalities in mast cell and erythrocyte development in Kit−/−, and early B cell development in Flt3−/− mice. These roles have been emphasized in vitro through the analysis of the effects of FLT3 and KIT ligands (FL and KL, respectively), on lympho-hematopoietic progenitors. Of interest is the recent observation that FL can stimulate the production of NK cells in vivo, as well as all types of dendritic cells in high numbers, which could be the basis of the antagonistic effect of FL on tumor development in animal models.
autophosphorylation of the receptor at a specific tyrosine (tyrosine 845 in the mouse), equivalent to tyrosine 1162 in the insulin receptor, and subsequent full activation of tyrosine kinase activity. 5 Additional tyrosines are then autophosphorylated and serve as a docking site for proteins of the signal transduction machinery. Targets that contact the activated FLT3 receptor include the adaptors GRB2 and the p85 subunit of phosphoinositide 3-kinase (PI3K). 6 Other molecules are also phosphorylated on tyrosines following FL stimulation but are not found associated with the receptor. Among these are the VAV exchange factor, the CBL and the CBLB related molecules, and the SHC protein, which was initially described as an adaptor for the RAS/RAF/MAP kinase pathway. 7, 8 Recent studies indicate that SHC might be connected to two different pathways leading to RAS activation and MYC transcription, through selective phosphorylation of tyrosines 239/240 and tyrosine 313, respectively. 9, 10 In hematopoietic cells, the SHC gene codes for two proteins of 46 and 52 kDa that result from the use of alternative translational start sites. SHC has two domains that can interact with tyrosines in a phosphodependent manner: (1) an N-terminal PTB domain that can interact directly with RTKs, such as the EGF (epidermal growth factor) and NGF (nerve growth factor) receptors, and with the SHIP inositol phosphatase in cytokine-stimulated hematopoietic cells; and (2) a C-terminal SH2 domain that binds to a specific tyrosine-based sequence in many receptors.
Our study was conducted to determine the tyrosine-phosphorylated sites on SHC that are targeted following FLT3 activation and to analyze the role of the PTB and SH2 domains in SHC phosphorylation. SHC function downstream of FLT3 was also evaluated by overexpressing wild-type and mutant SHC proteins in cytokine-dependent Ba/F3 cells. Finally, we have investigated the possible involvement of the SHIP negative regulator, which is a major SHC-binding protein in cytokine-stimulated cells, in FLT3 signaling.
Experimental procedures

Cell cultures
Interleukin-3 (IL3)-dependent Ba/F3 cells expressing the FMS/FLT3 chimeric receptor (Ba/F3-FF3 cells) 11 were routinely cultured in RPMI 1640 supplemented with 10% heat-inactivated (30 min 56°C) fetal calf serum (FCS), 0.8 mg/ml G418 and IL3 (produced as a supernatant of COS7 cells transiently transfected with the IL3 coding vector pCDSRa/IL3 kindly provided by DNAX, Palo Alto, CA, USA). M1 cells were grown in RPMI 1640 supplemented with 10% FCS.
Generation of retrovirus and retroviral infection
The retroviral packaging cell line GP+E was used for production of ecotropic viruses. GP+E cells transfections with pBABE vectors were carried out on 2 × 10 5 cells in 100 mm dishes using Lipofectin (Gibco BRL, Rockville, MD, USA) and 10 g of plasmid. Resistant cells were selected in medium containing 2 g/ml puromycine. For infection, 3 × 10 5 Ba/F3 cells pretreated with 2 g/ml protamine sulfate were cocultured with GP+E cells in six-well culture plates for 24 h. The Ba/F3 cells were then transferred to fresh medium containing 2 g/ml of puromycine for selection of infected cells.
Growth factors and antibodies
Recombinant M-CSF (macrophage colony-stimulating factor) was purchased from Prepro Tech (TEBU, Le Perray-Yvelines, France) and E. coli-produced murine FL was kindly provided by DNAX. Anti-phosphotyrosine monoclonal antibody (mAb) (4G10) and rabbit polyclonal anti-SHC antibodies were purchased from UBI (Lake Placid, NY, USA). Rabbit polyclonal anti-GRB2 (C23) and anti-SHIP (N1) antibodies and anti-MYC mAb (9E10) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A polyclonal rabbit antiserum specific for human and murine SHIP obtained by immunization with a GST-SHIP-SH2 fusion protein 12 was kindly provided by E Vivier (CIML, Marseille, France).
Cell stimulation and lysis
For the immunoprecipitation experiments, Ba/F3 cells were starved for 4 h in culture medium without IL3 and stimulated with 250 ng/ml of human M-CSF. Cells were then washed twice in ice-cold phosphate buffered saline (PBS) and lysed in 20 mM Tris-HCl pH 8, 2 mM EDTA pH 8, 1% Nodinet P-40 (NP40), 150 mM NaCl, 1 mM sodium orthovanadate, 6 g/ml antipain, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride. The lysates were cleared by centrifugation before immunoprecipitation.
Immunoprecipitation
Clarified cell lysates were incubated for 4-6 h at 4°C with 5 mg of agarose conjugated anti-MYC antibody or with 5 l of anti-SHIP antiserum or 5 g of SHC antibodies in the presence of protein-A coupled sepharose (Pharmacia, Uppsala, Sweden). Immune complexes were washed three times with lysis buffer and were heated in loading buffer containing SDS/2-mercaptoethanol and separated by polyacrylamide gel electrophoresis.
Western immunoblotting
Separated proteins from the polyacrylamide gels were transferred to Immobilon membrane (Millipore, St-Quentin-Yvelines, France) and the membrane probed with the indicated antibody at a concentration of 1 g/ml in PBS, 0.1% Tween-20, 0.5% non-fat dry milk, except for the 4G10 antibody which was diluted in Tris-buffered saline, 0.1% Tween-20, 0.5% bovine serum albumin. Horseradish peroxidase-coupled anti-mouse or anti-rabbit immunoglobulin antibodies (Dako, Trappes, France) were used for detection. For successive probing of the same membrane with different antibodies, stripping was performed in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.8 for 30 min at 50°C. Immunoblot quantitation was performed using MacBAS software (Fuji Photo Film, Tokyo, Japan).
Proliferation assay
5 × 10 4 cells were incubated in 50 l of medium (RPMI 1640, FCS 10%) with supernatant from IL3-producing Cos7 cells at 0.05, 0.1 and 0.2% or M-CSF at 50, 100 and 200 ng/ml for 24 h. Cells were then incubated for 6 h with 50 Ci 3 H-thymidine before harvest. Incorporated radioactivity was measured by liquid scintillation.
Results
Endogenous and MYC-tagged retrovirally encoded SHC proteins are tyrosine-phosphorylated in Ba/F3 cells upon FLT3 activation
We previously showed that SHC proteins are major substrates of the FLT3 RTK in murine and human hematopoietic cells. To dissect the molecular basis for SHC phosphorylation, we first analyzed the phosphorylation status of endogenous and retrovirally encoded SHC proteins in response to activation of a chimeric FMS/FLT3 (FF3) receptor in Ba/F3 cells. This chimeric receptor is activated by M-CSF but retains the signaling specificities dictated by the FLT3 intracellular domain.
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Exogenous SHC was tagged with a MYC epitope that allows specific recognition by a commercial mAb. 13, 14 As shown in Figure 1 , endogenous p46 and p52 SHC products were tyrosine-phosphorylated upon FF3 activation. MYC-tagged p52 SHC protein was phosphorylated in a similar way. Because MYCtagged p46 SHC has an electrophoretic mobility similar to immunoglobulin heavy chains, its phosphorylation could not be assessed. GRB2 is a major SHC-binding protein upon activation of a number of surface receptors, including FLT3. Endogenous (detected by anti-SHC IP) and exogenous (detected by anti-MYC IP) SHC had a similar capacity to bind GRB2 following FF3 activation in Ba/F3 cells ( Figure 1 ). The SHIP inositol phosphatase is the prominent tyrosine-phosphorylated SHC-binding protein in cells activated by various cytokines, an observation that has not been reported in the case of FLT3. The presence of a tyrosine-phosphorylated band around 145 kDa that was also recognized by anti-SHIP antibodies indicates that endogenous and exogenous SHC proteins bound tyrosine-phosphorylated SHIP. MYC-tagged SHC proteins behaved similarly to native SHC in FLT3-activated Ba/F3 cells, and were suitable for subsequent structurefunction analyses (see below).
Kinetic analysis of SHC phosphorylation and complex formation in response to FLT3 activation
To study the time-dependent phosphorylation of SHC, it was immunoprecipitated from Ba/F3-FF3 cells stimulated for various times with M-CSF. As shown in Figure 2 , SHC phosphorylation was very rapid and nearly maximal at the earliest time point (15 s) analyzed. This phosphorylation was sustained and remained above the background level for unstimulated cells even after 60 min stimulation. SHC phosphorylation strictly correlated with the phosphorylation of associated-SHIP which was detected as a 145 kDa band by the 4G10 mAb. In addition, Figure 2 shows that SHIP and GRB2 recruitment by SHC was quantitatively and temporally related to SHC phosphorylation.
FF3 stimulation induces SHC phosphorylation at tyrosine residues 239/240 and 313
For murine SHC, three tyrosine phosphorylation sites have been mapped to residues 239, 240 and 313. 9, 15 Phosphorylation of tyrosine 239 or 313 creates binding sites for the GRB2 adaptor. The precise function of tyrosine 240 is presently unknown but it could alter substrate recognition by phosphotyrosine 239. 16, 17 To determine which SHC tyrosines are targets for the activated FLT3 receptor, MYC-tagged wild-type SHC proteins, MYC-tagged mutant SHC proteins harboring Y to F mutations at residues 239/240, 313, or all three sites 13, 14 (see Figure 3a) were expressed in Ba/F3 cells following retroviral infection. Figure 3b shows that wild-type SHC and point mutants (lanes 1, 2, 3 and 4) were overexpressed compared to the endogenous SHC (lane −). Figure 4 shows that tyrosine phosphorylation of wild-type SHC, SHC Y239F/240F and SHC Y313F was easily detectable whereas the mutants harboring a mutation at all three tyrosines (Y3F) no longer showed reactivity with the anti-PY mAb. This would suggest that Y239/240 and Y313 were nearly equally phosphorylated and constitute the major, if not only,
Figure 2
Time-course analysis of SHC phosphorylation and association with SHIP and GRB2 following FF3 activation. 30 × 10 phosphorylated tyrosines of SHC in FLT3 activated cells. Interestingly, tyrosine phosphorylated SHIP still associated with Y239/240F, Y313F and Y3F, indicating that these residues are not necessary for SHC binding to SHIP. Blotting of the membrane with anti-GRB2 antibody indicated that the Y239/240 and Y313 residues are the only GRB2 binding sites in SHC.
Functional SHC PTB and SH2 domains are not necessary for phosphorylation
To investigate the role of phosphotyrosine binding domains of SHC, ie PTB and SH2 domains, mutant SHC proteins with inactivating point mutations of these domains (see Figure 3a and b, constructs 5 and 6) were expressed in Ba/F3 cells. Figure 4 shows that wild-type F198V and R397K SHC had comparable levels of M-CSF-induced tyrosine phosphorylation. A tyrosine-phosphorylated band that comigrates with SHIP was coprecipitated only with SHC proteins harboring an intact PTB domain, in agreement with a previous study. 18 In contrast, GRB2 binding was not affected by these two point mutations, indicating that the SH2 and PTB domains are dispensable for SHC phosphorylation and subsequent GRB2 binding.
Overexpression of SHC increases SHIP tyrosine phosphorylation
Recent studies have demonstrated that cytokine-induced SHIP phosphorylation requires an intact SHIP SH2 domain and that this domain may contact tyrosine 313 and/or 239/240 of SHC, thereby regulating GRB2 binding. 17, 19 To investigate the putative role of SHC in the initiation and maintenance of SHIP phosphorylation, we analyzed the status of SHIP phosphorylation after FF3 stimulation in Ba/F3 cells expressing wild-type and mutant SHC proteins. As shown in Figure 5 , SHIP phosphorylation was increased in cells overexpressing wild-type or SHC mutants, with the exception of SHC-F198V. In addition, an increase in the level of SHIP-associated GRB2 following FF3 activation, as compared to pBabe-infected control cells, was also easily observable in cells overexpressing either wild-type or mutant SHC again with the exception of SHC-F198V. This result suggests that PTB-dependent SHIP binding is a limiting step that controls SHIP phosphorylation.
SHC overexpression negatively regulates FLT3-dependent growth of Ba/F3-FF3 cells
In the following set of experiments, we quantitated the proliferation of Ba/F3 cells induced by M-CSF in the presence Analysis of phosphorylation of wild-type and mutant SHC proteins and association to GRB2 and SHIP following activation of FF3. Populations (same as in Figure 3b SHC overexpression in Ba/F3-FF3 cells increases SHIP tyrosine phosphorylation. Populations (same as in Figure 3b ) of Ba/F3-FF3 cells (30 × 10 6 ) infected with an empty retrovirus (lanes labeled pBabe) or SHC-coding retroviruses were left unstimulated (lanes labeled −) or stimulated for 2 min (lanes labeled +) with 250 ng/ml M-CSF. After lysis in 1% NP40, lysates were subjected to immunoprecipitation with a goat polyclonal anti-SHIP antibody and immunoprecipitates were separated by SDS-PAGE, transferred to Nylon membrane and subsequently probed with the indicated antibodies. SHIP bands are indicated by arrowheads.
or absence of retrovirally encoded wild-type or mutant SHC proteins ( Figure 6) . Surprisingly, we observed that overexpression of wild-type, Y239F/240F and R297K SHC proteins significantly decreased cell proliferation by 40%, 34% and 45%, respectively. Strikingly, we did not observe this negative effect when SHC was mutated at tyrosine 313. Mutation of the PTB domain restored proliferation to normal levels, but proliferation in the absence of M-CSF was increased as well. When the effect of IL3 was analyzed in a similar experiment, wild-type SHC had no effect on cell proliferation but mutations Y313F and F198V significantly increased cell proliferation by 30% and 42%, respectively. This data suggests that SHC can exert an antagonist effect on FLT3-dependent cell proliferation via a mechanism that depends on tyrosine 313.
A FLT3 mutant lacking GRB2 and p85 binding activity still induces SHC but not SHIP phosphorylation
We have previously demonstrated that the phosphotyrosine 958 of FLT3 constitutes a binding site for the SH2 domains of the p85 subunit of PI3K and GRB2, and that phosphotyrosine 769 can bind GRB2 via its SH2 domain as well 11, 20 (N Beslu, manuscript in preparation) (see Figure 7a) . Y972, which is included within a GRB2-binding consensus sequence, does not appear to be a functional binding site in vivo. In contrast to the wild-type receptor, FLT3 harboring Y → F point mutations at these three residues showed very little phosphorylation upon activation, indicating that they represent the principle autophosphorylation sites of the receptor (not shown). We tested the capacity of wild-type (WT) and triple mutant (TM) FF3 receptors to induce SHC and SHIP phosphorylation in Ba/F3 cells. The immunoblotting experiments shown in Figure 7b indicate that FLT3 tyrosines 769, 958 and 972 are dispensable for SHC phosphorylation. In contrast, SHIP was barely phosphorylated in Ba/F3 cells expressing the tyrosine-mutated FF3. In these cells, we did not observe an increase in GRB2 binding to SHIP and very little SHC (as evidenced by the anti-PY-reactive band comigrating with p52 SHC ) associated with SHIP upon activation.
Activation of endogenous FLT3 by FL in M1 monocytic cells induces SHC and SHIP phosphorylation
Because the experiments in the present study were performed in Ba/F3 cells expressing an exogenous FMS/FLT3 chimera, we wished to demonstrate that the observed biochemical effects were similar upon FL activation of murine M1 cells, which express endogenous FLT3. Figure 8 demonstrates that FL treatment induced tyrosine phosphorylation of SHC and SHIP and an increase in SHC binding to SHIP and GRB2, similar to that observed in Ba/F3-FF3 cells. Unfortunately, we could not infect M1 cells with SHC retroviruses because retrovirus-containing supernatants induced the differentiation of these cells to macrophages, resulting in cell growth arrest and FLT3 down-regulation.
Discussion
The FLT3 receptor and its ligand FL, are key regulators of early hematopoiesis and monocytic development. 1 In addition, promising clinical applications for FL are envisioned because of its capacity to strongly mobilize bone marrow hematopoietic stem cells in combination with G-GSF, 21, 22 and its ability to induce the production of dendritic 23 and natural killer 2 cells in vivo making it even more attractive for cancer immunotherapy. 4 It is therefore important to characterize the biochemical events downstream of the FLT3 receptor. Indeed, it is possible that FLT3 signaling molecules could one day become useful tools for increasing its clinical potential. Our recent studies have revealed that the SHC, CBL and CBLB cytoplasmic components of the signal transduction cascade are prominent tyrosine-phosphorylation substrates upon activation of human hematopoietic cell lines by FL. 7, 8 SHC proteins are believed to connect to the RAS pathway via a unique interaction between the SH2 domain of GRB2 and phosphorylated tyrosine 317 (in humans, 313 in the mouse), a residue lying within the central collagen homology domain of SHC. Recently, it has been shown that tyrosines 239 and 240 can also be phos- phorylated, and constitute a second binding site for GRB2. 9, 16 Depending on the cell type and stimulus used, phosphorylation at this site has been proposed to initiate a RAS-independent cascade that culminates, at least, in MYC transcription 9, 10 or to reinforce GRB2 binding to SHC to efficiently recruit the SOS GDP/GTP exchange factor. 24 We demonstrate in the present work that activation of the FLT3 kinase in Ba/F3-FF3 cells targets phosphorylation of SHC at tyrosines 239/240 and 313 and that both sites are able to bind GRB2 equally well. GRB2 binding indicates that both tyrosines 239 and 313 are indeed phosphorylated, because phosphorylation of Y240 alone is unable to provide an SH2-binding site for GRB2. 16 The phosphorylation status of Y240 in our system remains unknown.
There are three isoforms of SHC (p46, p52 and p66); the former two are composed of an N-terminal PTB domain and a C-terminal SH2 domain situated on either side of a central collagen homology (CH) domain. 15 p66 SHC, which is not expressed in Ba/F3 cells, possesses an additional N-terminal CH domain. Both the SH2 and PTB domains of SHC bind with high affinity to tyrosine phosphorylated residues lying within the cytoplasmic domain of RTKs. In addition, the SHC PTB domain is able to bind acidic membrane phospholipids, in particular phosphatidylinositol-4-phosphate (Ptdlns(4)P). 25 The F198 → V mutation in the SHC PTB domain specifically SHC and SHIP in FLT3 signaling S Marchetto et al 1380 affects binding to phosphotyrosines but not phospholipids [25] [26] [27] and is not necessary for SHC phosphorylation (Figure 4 ). Similarly, an inactivating mutation in the SH2 domain of SHC does not preclude SHC phosphorylation. This might be related to the inability of the FLT3 receptor to form a complex with SHC (our personal observation), in contrast to other RTKs such as the EGF receptor, which binds to SHC through both the PTB and SH2 domains. 28 The specific requirements for SHC phosphorylation upon FLT3 activation are clearly different from what has been described upon activation by IL3 26 where SHC must not only be recruited to the membrane in a phospholipid/PTB-dependent manner, but must also be able to contact the tyrosine phosphorylated ␤ c chain of the IL3 receptor, also through its PTB domain. One can suggest that FLT3-dependent SHC phosphorylation is solely dependent upon its recruitment to the membrane via phospholipids. Interestingly, it has recently been shown that SRC is able to phosphorylate SHC at tyrosine residues 239 and 240 in a Ptdlns(4,5)P 2 /PTB dependent manner. 29 Because a RAS-independent 'SRC pathway' has been suggested to culminate in MYC transcription and DNA synthesis in response to activation of the FLT3-related platelet-derived growth factor (PDGF) and M-CSF receptors, 30 it is possible that SRC-related kinases are recruited and activated at the FLT3 juxtamembrane domain and mediate SHC phosphorylation without direct FLT3/SHC interaction. Accordingly, the tyrosine residue (Y590 in the mouse) that should contact the SRC/SRC-like SH2 domain is intact in the FLT3 TM mutant which is still able to phosphorylate SHC. Furthermore, we demonstrate that the SH2 domain of SHC is dispensable for phosphorylation arguing again that phosphotyrosine-dependent recruitment of SHC to the FLT3 receptor or to another protein is not necessary.
Extensive studies have been carried out to delineate the signal transduction pathways involved in the positive regulation of cell proliferation induced by growth factors and cytokines. Little is known, however, about the mechanisms which regulate the termination of cellular signaling, thereby avoiding oncogenic transformation. In the case of the RTKs, in particular those that belong to the FLT3-containing class III, 31 two candidates have recently emerged as negative regulators. The first one is SHP1 which has been shown by both genetic and biochemical approaches to attenuate proliferation induced by FMS (M-CSF receptor) and KIT (SCF receptor). [32] [33] [34] The second is CBL which enhances ubiquitination and degradation of the platelet-derived growth factor receptor ␣.
35 SHP1 and CBL can also negatively regulate signaling pathways downstream of receptors such as the erythopoietin receptor 36 and antigen receptors at the surface of T 37 and B cells. 38 In B cells, SHIP has been functionally and biochemically characterized as a negative regulator of antigen receptor signaling by inhibiting Ptdlns(3,4,5)P 3 -dependent membrane recruitment of the BTK tyrosine kinase. 39, 40 In the present study, a 145 kDa protein that we identify as SHIP constitutes the major tyrosine phosphorylated SHCassociated protein in FLT3-stimulated cells. The same association is observed in response to activation of the FMS (M-CSF receptor) 41 and most, if not all, cytokine receptors, 42 as well as antigen receptors on B and T cells. 43, 44 At the present time, very little is known about the functional consequences of this complex.
Our work demonstrates that the binding of SHIP to SHC requires an intact SHC PTB domain which probably interacts with two NPXY phosphorylated sites found at the carboxyterminus of SHIP. 18 SHC phosphorylation is neither necessary nor sufficient for this interaction, as previously proposed by Lamkin et al, 18 in contrast to the conclusions of Liu et al. 45 Moreover, we were not able to precipitate SHC in a GST pull down assay using the isolated SH2 domain of SHIP under conditions that permit efficient precipitation of SHC by a GRB2 GST fusion protein (not shown). The lack of SHIP inducible phosphorylation by the FLT3 TM mutant suggests that SRClike kinases are not involved in this process. The fact that FLT3 TM is no longer able to bind PI3K, and consequently to generate SHIP substrates, would argue that sustained SHIP phosphorylation is controlled by the quantity of substrate available through an allosteric regulation. In contrast, the level of SHIP tyrosine phosphorylation is increased upon overexpression of wild-type SHC or mutant SHC proteins bearing a functional PTB domain. This raises the possibility that SHC/SHIP complex formation constitutes a rate-limiting step for SHIP phosphorylation. Prevention of tyrosine dephosphorylation at a particular site by SH2 domain binding has been demonstrated in the cases of LCK 46 and the EGF receptor 47 and thus may be extrapolated to phosphotyrosine/PTB interactions. As SHIP phosphorylation and association to SHC does not affect its intrinsic enzymatic activity, 42 recruitment by SHC may be necessary for regulating SHIP localization and/or accessibility to lipid substrates.
Our proliferation assays show that SHC can exert a negative regulatory effect on cell proliferation induced by FLT3 which is reversed upon mutation of tyrosine 313, suggesting a role for this residue in an inhibitory process. In addition, we observed a higher percentage of cell death upon M-CSF deprivation of Ba/F3-FF3 cells overexpressing SHC but not Y313F (data not shown). SHC overexpression has been associated with tumorigenic activity 48 and enhanced proliferative responses to cytokines. 49 However, there is accumulating evidence that growth-promoting molecules such as RAS, which promote cell survival through activation of the PI3K/PKB pathway, can induce apoptosis as well. 50 To determine whether GRB2 binding at tyrosine 313 initiates a death-inducing signal mediated by the RAS/RAF/MAP kinase pathway 50 will require further investigation. Interestingly, Terada et al 5 have shown that RAS is not necessary for IL3-induced proliferation of Ba/F3 cells, leaving open the possibility that some of the RAS effectors may be deficient in these cells, revealing unexpected functions for SHC. Our results shown in Figure 6 do not favor a role for SHIP in the negative effect of SHC on M-CSFinduced cell proliferation as the F198V mutant, which is unable to recruit SHIP, does not reverse this effect. Overexpression of wild-type SHC had no effect on IL3-induced cell proliferation in contrast to SHC-Y313F and SHC-F198V that increased IL3 mitogenicity. This confirms that Y313 possibly initiates an inhibitory pathway and suggests a possible negative role for SHIP recruitment by SHC following IL3 receptor, but not FLT3, activation. It is thus conceivable that SHC initiates both positive and negative responses that are differentially balanced upon the cytokine used, with a net effect that is null in the case of IL3 but negative for FLT3, in our model of transfected Ba/F3 cells. Interestingly, we have recently demonstrated that Y239/240, and to a lesser extent Y313, exert a negative effect on the transforming activity of the VEGFR3 RTK. 14 Recently, it has been proposed that SHIP exerts its negative regulatory activity by inhibiting GRB2 binding to SHC. 52 Our inability to precipitate SHC with an isolated SHIP SH2 domain (see Discussion above) and our kinetic analysis of SHIP and GRB2 association with SHC do not fit with this model, since they are both simultaneously recruited by SHC.
In conclusion, we have demonstrated that FLT3 is able to phosphorylate SHC at tyrosine 239/240 and 313 as well as SHIP, upon activation. These two molecules then associate with each other in a PTB-dependent manner that protects SHIP from dephosphorylation. Overexpressed SHC negatively regulates cell growth induced by FLT3 activation by a mechanism involving Y313. This study provides a good example of the fine tuning that is required to integrate proliferative and counterproliferative effects which are partly mediated by the same molecules such as SHC or RAS.
